Viewing Study NCT00297921



Ignite Creation Date: 2024-05-05 @ 4:41 PM
Last Modification Date: 2024-10-26 @ 9:23 AM
Study NCT ID: NCT00297921
Status: WITHDRAWN
Last Update Posted: 2013-11-06
First Post: 2006-02-27

Brief Title: A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy
Sponsor: Millennium Pharmaceuticals Inc
Organization: Millennium Pharmaceuticals Inc

Study Overview

Official Title: None
Status: WITHDRAWN
Status Verified Date: 2013-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Prospective nonrandomized noncomparative open-label multicenter 2-stage clinical study designed to determine the overall response combined complete remission complete remission with incomplete blood count recovery partial remission or blast response rate following tandutinib therapy in 2 groups of patients with newly diagnosed Acute Myelogenous Luekemia
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None